---
title: "Theriva Biologics, Inc. (TOVX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/TOVX.US.md"
symbol: "TOVX.US"
name: "Theriva Biologics, Inc."
industry: "Biotechnology"
---

# Theriva Biologics, Inc. (TOVX.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [erivabio.com](https://erivabio.com) |

## Company Profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the trea...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.27 | 109/606 | - | - | - |
| PB | 1.06 | 89/606 | 1.01 | 0.35 | 0.20 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-26T05:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 50% |
| Overweight | 0 | 0% |
| Hold | 1 | 50% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.19 |
| Highest Target | 7.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/TOVX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/TOVX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/TOVX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.